Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
about
Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.Stem cell-derived endothelial cells for cardiovascular disease: a therapeutic perspective.A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixaforPlerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patientsLimiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftmentAdult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling.Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT.CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells.Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia RegistryGenetics on a WHIM.Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.Novel strategies for blood stem cell mobilization: special focus on plerixafor.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Novel agents and approaches for stem cell mobilization in normal donors and patients.Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.Current clinical indications for plerixaforPlerixafor for mobilization of blood stem cells in autologous transplantation: an update.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations.Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.New strategies for stem cell mobilization.Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization.Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation.Poor hematopoietic stem cell mobilizers in multiple myeloma: a single institution experience.Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent.Blood graft composition after plerixafor injection in patients with NHL.Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
P2860
Q27692619-E843D583-1B41-42C4-AADF-EBB0965C01F8Q34016950-C4F22A13-BCED-4196-B52E-3E8E3072FC23Q34213411-4AA3E3AD-1083-46B0-A0DB-699A7ACF0959Q34306425-81886209-E74B-4F03-A93E-A820493420E9Q34403975-1CFB47C1-D4DF-4DD9-B968-AB684221EC10Q34454624-E83FC657-BE6C-4797-BD0F-868127DB8575Q35475882-E9C14873-6BDD-41AE-A4B4-43EE2C6D6826Q35788749-E7B1DA23-2CBC-40AA-9517-E32D6D5EBE28Q35965373-2ACEE359-647E-4393-B91C-463CCAB6A4BCQ36028820-FD072F8E-FD1E-482C-AA9E-8F84FA19CA01Q36445393-6FB9188D-FFA2-49B3-8DB8-D74C31C33B23Q36569033-C71F3E2D-432A-4BA6-ADE4-C55741A3913CQ36649222-0CF952B7-E0F3-4EB4-A079-7093B23D0CE6Q37653020-A079DFF1-642F-4B65-AA27-84790CBA3151Q37785509-6063491E-50BE-480A-8420-99AE19CE2A52Q37827058-1B718F4F-7FB8-474F-AAEC-D043FEBCE2B1Q37909447-429296B1-2FFB-4E14-998C-3E9CD85C4CFFQ37921284-D27BA214-8B19-4F89-887F-5679286F5812Q37923309-5BD310C8-5BFF-4F42-9012-EB17E1AABF0EQ37943423-43E5CA89-75C6-4CE2-A941-C8696D8FDFF4Q38077807-AD114348-B11F-4F57-85BE-CFBB06E93AF1Q38177784-02A3D2D7-3AF6-4225-976B-FBC17868CC72Q38199707-BD2EA37C-D081-4CAF-96CC-7E0BF04EC4E6Q38200909-7B52CEAF-3B56-4333-92AE-898734280792Q38210641-AC506587-3BAA-4A58-A8A3-EEEF281945FFQ38880504-4C467A25-FE52-4BFD-91A4-92D5CC25EB43Q39724267-7BC4CC16-093E-4F87-A6CD-DBBA85BB3BA1Q39958361-83AD4E64-7BB2-4817-B776-70948D16CE4FQ40407349-1B7F80CF-986D-477D-B4A8-DDE95430D927Q40896003-C8FA170A-7A63-4891-9613-31C6273EA668Q41104670-260E86C5-CBF5-499D-BF12-29D9872BE3F2Q42133489-FB2D852F-185F-4C17-9D4D-8B9B7D73DE2DQ42184785-6CA93B66-428A-48B0-8524-0687CCB4A190Q42588899-40D761ED-18A6-4FA8-A8C0-A84B6B2FB919Q43524297-23421A1A-E782-4A07-A1F2-DF9A468469DEQ43563982-DC7FC358-809E-4009-87D6-F2A2AAE02C5AQ44353274-E5250457-DD7C-4B31-9D15-066531E6E9A8Q44556507-782EAA59-934B-4211-B6F6-C2566DF0C2DBQ44607102-D8B75383-B401-4D72-B37A-760722008DE4Q44894394-B88C5291-17FE-4211-90DB-A93ACD91A615
P2860
Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Safety and preliminary efficac ...... rgoing stem cell mobilization.
@en
Safety and preliminary efficac ...... rgoing stem cell mobilization.
@nl
type
label
Safety and preliminary efficac ...... rgoing stem cell mobilization.
@en
Safety and preliminary efficac ...... rgoing stem cell mobilization.
@nl
prefLabel
Safety and preliminary efficac ...... rgoing stem cell mobilization.
@en
Safety and preliminary efficac ...... rgoing stem cell mobilization.
@nl
P2093
P2860
P356
P1476
Safety and preliminary efficac ...... rgoing stem cell mobilization.
@en
P2093
A Nademanee
G Calandra
J Liesveld
R T Maziarz
W I Bensinger
P2860
P2888
P356
10.1038/BMT.2009.119
P407
P577
2009-06-01T00:00:00Z
P5875
P6179
1032656035